Anavex Life Sciences Corp (AVXL)

[falconer66a]

Thanks. That clarifies the issue.

My issue is not with the science. It’s with senior (mis)management and the clubby BOD.

In all due respect, my thanks for this statement. I'll summarily discard my momentary anxiety about my small AVXL position (contrived as it was).

The results of the Parkinson's disease dementia and Alzheimer's Phase 3 trials of blarcamesine, when they appear later this year or next, will settle everything. If they are profoundly positive, allowing (or mandating) FDA approvals of blarcamesine for the two CNS afflictions, Missling's putative mismanagement will be unable to slow or inhibit such approval. It'll happen no matter what. FDA doesn't approve drugs based upon the management styles of corporate executives. The only things that count are Phase 3 clinical trial results data.

On the other hand, if both of the trials fail, showing that blarcamesine can't be a useful CNS disease therapeutic, Missling's previous 'mismanagement' of the company becomes irrelevant. If he can't manage or announce anticipated successes, how could he have been more effective in the long pre-clinical periods (right now)?

In the end (well, the company's actual beginning, as a commercial success), the only thing that will count will be the results of the two big Phase 3 studies. If either is positive, Anavex Life Science Corp moves quickly to commercial success. If both of them fail, there can be no near-term future for the company.

Phase 3 clinical results are the only things that count. After definitive clinical successes or failures, Missling's earlier management styles will be forgotten; utterly irrelevant.